Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid in Pediatric Biliary Atresia
NCT05321524Phase 2Terminated
- Sponsor
- Intercept Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 2, open-label trial of obeticholic acid in biliary atresia (3 cohorts), sponsored by Intercept Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events at Day 56 and Plasma concentration of OCA and its conjugates at Day 56. Started Jul 2015; status: terminated.
02
Drugs
obeticholic acid
03
Conditions
biliary atresia
Beyond the preview
Go deeper on NCT05321524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321524.